CHCWM – Cancer & Hematology Centers of West Michigan

NGM707 (NGM Biopharmaceuticals)

A Phase 1 / 2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies